Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study

Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study

Abstract Background IDegLira is a fixed-ratio combination of insulin degludec and liraglutide with proven efficacy against simpler regimens and non-inferiority against basal-bolus insulin therapy. However, the evaluation of its real-world effectiveness is hindered by technical issues and requires fu...

Full description

Bibliographic Details
Main Authors:	Sándor Szépkúti, Szilvia Bandur, Gábor Kovács, Tamás Ferenci, Márk M. Svébis, Piroska Turbucz, Ádám G. Tabák
Format:	Article
Language:	English
Published:	BMC 2022-09-01
Series:	BMC Endocrine Disorders
Subjects:	Insulin therapy; liraglutide; type 2 diabetes mellitus GLP-1 agonists Basal insulins Cohort study
Online Access:	https://doi.org/10.1186/s12902-022-01139-8

Similar Items

Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting
by: Alex Ramírez-Rincón, et al.
Published: (2022-04-01)

Early Conversion of Intensive Insulin Therapy to IDegLira Demonstrates Higher Efficacy and Safety in Reducing Fasting Blood Glucose and HbA1c in T2DM Patients
by: Guo C, et al.
Published: (2024-08-01)

One‐year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes
by: Zoltán J. Taybani, et al.
Published: (2023-01-01)

Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China.
by: Dunming Xiao, et al.
Published: (2025-01-01)

Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US
by: Lin J, et al.
Published: (2016-12-01)

Liraglutide Attenuates Glucolipotoxicity-Induced RSC96 Schwann Cells’ Inflammation and Dysfunction
by: Edy Kornelius, et al.
Published: (2022-09-01)

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
by: Marvin Wei Jie Chua
Published: (2021-12-01)

Editorial: Incretin agonists in the treatment of obesity
by: Xiaodong Sun, et al.
Published: (2023-08-01)

Preoperative liraglutide modulates control of fat and glucose metabolism during cardiopulmonary bypass surgery
by: Robert van Wilpe, et al.
Published: (2025-02-01)

United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
by: Rendell M
Published: (2017-04-01)

Fabrication and Evaluation of a pH-Responsive Nanocomposite-Based Colonic Delivery System for Improving the Oral Efficacy of Liraglutide
by: Song JG, et al.
Published: (2023-07-01)

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
by: Khang Duy Ricky Le, et al.
Published: (2024-01-01)

Comparison of Postprandial Insulin Levels in Withania Coagulans and Liraglutide Treated Diabetic Rats
by: Abdul Samad, Shazia Ali, Noman Sadiq
Published: (2018-12-01)

Natural history of ROHHAD syndrome: development of severe insulin resistance and fatty liver disease over time
by: Abdel Wahab Jalal Eldin, et al.
Published: (2019-07-01)

Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression
by: Amr Ahmed, et al.
Published: (2024-07-01)

Biotechnology Revolution Shaping the Future of Diabetes Management
by: Nilima Rajpal Kundnani, et al.
Published: (2024-12-01)

Understanding the link between type 2 diabetes mellitus and Parkinson’s disease: role of brain insulin resistance
by: Theodora Ntetsika, et al.
Published: (2025-11-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

Hippocampal Ganglioside Composition is Altered by Metformin and Liraglutide Treatment in A High-Fat High-Sugar Diet Rat Model
by: Marin Kuharić, et al.
Published: (2023-01-01)

Glucagon-like Peptide-1 Receptor Agonists: Are They as Good as They Seem? A Systematic Review of Severe Adverse Effects
by: Pranjal Sharma, et al.
Published: (2024-08-01)

Treatment of insulin resistance with tirzepatide leading to improvement of hair loss
by: Emily R. Gordon, BA, et al.
Published: (2024-08-01)

Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer’s disease
by: Noor Abdulhameed, et al.
Published: (2024-08-01)

Issues of insulin therapy for type 2 diabetes and ways to solve them
by: V.I. Katerenchuk, et al.
Published: (2023-05-01)

Excessive accumulation of epicardial adipose tissue promotes microvascular obstruction formation after myocardial ischemia/reperfusion through modulating macrophages polarization
by: Jinxuan Zhao, et al.
Published: (2024-07-01)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
by: Neff LM
Published: (2010-07-01)

Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
by: Lyudmila Alexandrovna Ruyatkina, et al.
Published: (2017-06-01)

Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy
by: Pöhlmann J, et al.
Published: (2019-10-01)

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
by: Sanjay Kalra, et al.
Published: (2016-01-01)

Label-free quantitative proteomic profiling reveals differential plasma protein expression in patients with obesity after treatment with liraglutide
by: Afshan Masood, et al.
Published: (2024-09-01)

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
by: Alessandro Mantovani, et al.
Published: (2021-01-01)

Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype
by: Toomas Jagomäe, et al.
Published: (2021-11-01)

Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options
by: Arturo Cesaro, et al.
Published: (2023-07-01)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
by: Daiji Kawanami, et al.
Published: (2020-06-01)

Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s
by: Andrea Etrusco, et al.
Published: (2024-03-01)

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
by: Ana Petrovic, et al.
Published: (2023-05-01)

Effect Of Withania Coagulans And Liraglutide On Serum Glp-1, Postprandial And Fasting Blood Glucose In Streptozotocin Induced Diabetic Rats
by: Abdul Samad, et al.
Published: (2019-06-01)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)

Evaluation of Liraglutide Effect on Serum Adipocytokines of Adults Male Wistar Rats with Insulin Resistance That Induced by High Fat Diet
by: Furqan Mohammed Abdulellah, et al.
Published: (2018-12-01)

Association of serum fetuin-B with insulin resistance and pre-diabetes in young Chinese women: evidence from a cross-sectional study and effect of liraglutide
by: Xuyun Xia, et al.
Published: (2021-08-01)

A review of the efficacy and safety of the finished fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes mellitus
by: A. S. Pogorelova
Published: (2018-07-01)